Results 141 to 150 of about 45,197 (186)

PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer. [PDF]

Cochrane Database Syst Rev, 2021
Taylor AM, Chan DLH, Tio M, Patil SM, Traina TA, Robson ME, Khasraw M.   +6 more
europepmc   +1 more source

Myelin Impairment and Regeneration in the Central Nervous System: Molecular Mechanisms, Diseases, and Prospective Therapeutic Targets

MedComm, Volume 7, Issue 10, October 2026.
Proper myelin formation is crucial for normal neural circuit function, while myelin deficiency can lead to neural circuit dysfunction and cognitive decline, notably in Alzheimer's disease and other central nervous system demyelinating disorders. This review summarizes central myelin's structure and function, demyelination biomarkers and pathological ...
Lihong Huang, Peng Cheng, Guangdong Liu, Yang Xiang, Zhen Hong, Weidong Le   +5 more
wiley   +1 more source

Efficacy and safety of poly ADP-ribose polymerase inhibitors (PARPis) in extensive-stage small-cell lung cancer (ES-SCLC) treatment: a systematic review and meta-analysis. [PDF]

J Thorac Dis
Cheng CC, Ma LJ, Pang XM, Huang TS, Wang MF, Xu JY, Wang RQ, Chen X, Sun K, Zhao WX, Yan M, Wang P.   +11 more
europepmc   +1 more source

Targeting Krebs-cycle-deficient renal cell carcinoma with Poly ADP-ribose polymerase inhibitors and low-dose alkylating chemotherapy. [PDF]

Oncotarget, 2022
Ueno D, Vasquez JC, Sule A, Liang J, van Doorn J, Sundaram R, Friedman S, Caliliw R, Ohtake S, Bao X, Li J, Ye H, Boyd K, Huang RR, Dodson J, Boutros P, Bindra RS, Shuch B.   +17 more
europepmc   +1 more source

Ineffectiveness of immune checkpoint inhibitors in prostate cancer: is it just a question of ‘‐mabs’?

The Journal of Pathology, Volume 270, Issue 2, Page 139-162, October 2026.
Abstract Prostate cancer (PCa) is the second most common type of neoplasm, currently treated with a variety of therapeutic agents. Although advances in treatment over the past decade have improved overall survival, patients with advanced PCa eventually progress from hormone‐sensitive PCa to metastatic castration‐resistant PCa.
Giuseppe Schepisi, Irene Torresan, Emilio Francesco Giunta, Sara Bleve, Nicole Brighi, Elisa Tassinari, Sofia Zanuccoli, Maria Concetta Cursano, Cristian Lolli   +8 more
wiley   +1 more source

Novel clinical potential of poly (ADP‑ribose) polymerase inhibitors in triple‑negative breast cancer: Mechanistic insights and clinical applications (Review). [PDF]

Oncol Lett
Han Y, Wei L.
europepmc   +1 more source

RAD21 Confers Poor Prognosis and Affects Ovarian Cancer Sensitivity to Poly(ADP-Ribose)Polymerase Inhibitors Through DNA Damage Repair. [PDF]

Front Oncol, 2022
Gou R, Li X, Dong H, Hu Y, Liu O, Liu J, Lin B.   +6 more
europepmc   +1 more source

Chromodomain Helicase DNA–Binding Proteins and Spermatogenesis: Current Advances

Andrology, Volume 14, Issue 7, Page 1962-1970, October 2026.
ABSTRACT Background Male infertility is a prevalent clinical condition, with approximately one‐third of cases classified as idiopathic, frequently stemming from impaired spermatogenesis because of dysregulated gene expression. Chromodomain helicase DNA‐binding (CHD) proteins are central chromatin remodelers that orchestrate this epigenetic regulation ...
Mingrui Zhang, Di Liu, Guoqiang Liu, Minggang Zhu, Feng Pan   +4 more
wiley   +1 more source

Clinical Outcomes of Poly(ADP-Ribose) Polymerase Inhibitors as Maintenance Therapy in Patients with Ovarian Cancer in the Southeastern Region of Korea. [PDF]

Curr Oncol
Ha HI, Yoon HJ, Song C, Kim ET, Suh DS, Kim KH, Na YJ, Song YJ.   +7 more
europepmc   +1 more source

Ablative radiotherapy in castration‐resistant prostate cancer

BJU International, Volume 138, Issue 4, Page 659-665, October 2026.
Objective To prove the oncological benefit of ablative radiotherapy in patients with up to five metastases from castration‐resistant prostate cancer (CRPC) a single‐centre randomised trial was initiated. Patients and Methods This monocentric, randomised, phase II clinical trial enrolled patients with up to five prostate‐specific membrane antigen ...
Tobias Hölscher, Fabian Lohaus, Lydia Koi, Jörg Kotzerke, Sebastian Hoberück, Christian Thomas, Angelika Borkowetz, Steffen Löck, Mechthild Krause, Esther G.C. Troost   +9 more
wiley   +1 more source